Elizabeth O. Hexner

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

56h-index14.4kcitations479works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(144), Hematopoietic Stem Cell Transplantation(109), Myeloproliferative Neoplasms: Diagnosis and Treatment(83), Acute Myeloid Leukemia Research(79), Immune Cell Function and Interaction(43)

Publications479 total

Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S10 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia
Blood·2025
Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology
Blood·2025
Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia
Blood·2025Open Access
IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia
Blood·2025Open Access
CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL
Blood·2025Open Access
CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia
Blood·2025
page 1 of 24Next →

Frequent Co-authors

Carl H. June(13), Noelle V. Frey(12), Edward A. Stadtmauer(11), Ruben A. Mesa(10), Jason Gotlib(10), Wei‐Ting Hwang(10), Simon F. Lacey(9), Saar Gill(9), Selina M. Luger(9), Alison W. Loren(9), Srđan Verstovšek(8), Stephen G. Emerson(8), David L. Porter(8), Michael W. Deininger(7), Richard T. Silver(7), Joseph A. Fraietta(7), Bruce L. Levine(7), Ran Reshef(7), Vikas Gupta(6), Moshe Talpaz(6)